The most utilized ultrasound enhancing agent is approved for use in pediatric patients
Data on file, Lantheus.
Contrast Echo: See the Difference, Experience the Impact
Jonathan R. Lindner, MD, FACC, FASE, Lissa Sugeng, MD, MPH, FACC, FASE, Rajesh Janardhanan, MD, MCRP, FACC, FASE present the Lantheus 2015 ASE Science & Technology Theater Program.
Reduced resource utilization and per-patient expenses2,3
Eliminated the need for redundant tests by 33%2
Associated with changes in use of vasoactive medications3
Reduced struggle time and may limit sonographer injury4,5*
*Additional studies may be needed.
Decreased
procedure time4
May increase
patient throughput4,5
Lantheus offers multiple peer-to-peer programs to increase echo quality, enhance lab efficiency, reduce cost, and improve patient care.
DEFINITY® is committed to delivering customer value through the IMPROVE quality program.
References:
Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr. 2018;31(3):241-274.
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122.
Lester SJ, Askew JW, Hurst RT, et al. Contrast echocardiography: experience in a clinical echocardiography laboratory. J Am Soc Echocardiogr. 2006;19(7):919-923.
Castello R, Bella JN, Rovner A, Swan J, Smith J, Shaw L. Efficacy and time-efficiency of a “sonographer-driven” contrast echocardiography protocol in a high-volume echocardiography laboratory. Am Heart J. 2003;145(3):535-541.
DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
References: